Supporting HAE Commercial Teams with Prognos Health Lab Data

Hereditary angioedema (HAE) is a rare and debilitating condition affecting an estimated 1 in 50,000 individuals, characterized by recurrent episodes of swelling that can affect various parts of the body, including the potentially life-threatening airway. Diagnosis can be delayed, with some patients experiencing symptoms for years before receiving an accurate diagnosis, resulting in a reported average time to diagnosis of 7-10 years. Effective management is crucial, and commercial teams play a vital role in ensuring access to life-changing therapies. Prognos Health is committed to supporting these teams by providing valuable lab data insights that can streamline their efforts and improve patient outcomes.

The Diagnostic Challenges of HAE

Diagnosing HAE can be complex. The condition mimics other forms of angioedema and requires specific testing to confirm. As outlined in the HAE Summary Sheet, key diagnostic indicators include:

• Recurrent episodes of angioedema without urticaria (hives) lasting 2-5 days.
• Ineffective response to high-dose antihistamines.
• Absence of triggers like ACE inhibitors, NSAIDs, or allergies.

When HAE is suspected, specific complement tests are essential: C4, C1INH protein level, and C1INH function. These tests, however, are susceptible to lab errors and require careful handling and interpretation. Furthermore, the wide normal range for C4 and potential interference from certain medications add to the diagnostic complexity.

How Prognos Health Lab Data Can Help

Prognos Health understands these challenges and offers solutions designed to support commercial teams:

• Enhanced Targeting: Prognos Health's lab data can help identify patients with confirmed HAE diagnoses, allowing for more targeted outreach and educational initiatives. This ensures that resources are directed to the patients who need them most.
• Improved Patient Identification: By leveraging Prognos Health's extensive lab data coverage, commercial teams can identify patients whose lab results might indicate HAE, even if they haven't received a formal diagnosis. Our data includes a broad range of diagnostic markers, including C4, C1INH protein level, and C1INH function, enabling the identification of potential HAE patients across diverse healthcare settings. This can prompt further investigation and potentially expedite the diagnostic process, leading to earlier treatment.  
• Data-Driven Insights: Prognos Health's data provides valuable insights into patient populations, treatment patterns, and unmet needs. This information can inform marketing strategies, sales efforts, and educational programs, leading to more effective engagement with healthcare providers and patients.
• Streamlined Commercial Operations: Access to comprehensive lab data can streamline commercial operations, allowing teams to focus on building relationships with key stakeholders and ensuring patient access to critical therapies.

The Importance of Accurate Diagnosis and Timely Treatment

The availability of effective therapies for acute HAE attacks, including C1INH concentrates (Cinryze, Haegarda, Berinert), recombinant C1INH (Ruconest), icatibant (Firazyr), and ecallantide (Kalbitor), underscores the importance of accurate and timely diagnosis. These therapies can significantly reduce the severity and frequency of attacks, improving patients' quality of life.

Partnering for Better Patient Outcomes

Prognos Health is dedicated to partnering with commercial teams to improve the lives of HAE patients. By providing access to comprehensive and reliable lab data, we support these teams to:

• Accelerate diagnosis and treatment.
• Increase awareness of HAE and available therapies.
• Improve patient access to life-changing medications.

If you want to learn more about how we can help your commercial team reach more HAE treating providers and patients, let's talk.